14 analysts have shared their evaluations of Biogen (NASDAQ:BIIB) during the recent three months, expressing a mix of bullish and bearish perspectives. The following table summarizes their recent ...

Biogen recently received Fast Track designation from the FDA for its Alzheimer's therapy, BIIB080, signaling a significant advancement in its drug development ambitions. However, despite these ...

Biogen's results beat estimates on strength in rare disease drugs Biogen beat first-quarter profit and revenue expectations on Thursday, as strong demand for its rare disease drugs helped offset ...